These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 36571300)

  • 1. Vortioxetine - pharmacological properties and use in mood disorders. The current state of knowledge.
    Krupa AJ; Wojtasik-Bakalarz K; Siwek M
    Psychiatr Pol; 2023 Dec; 57(6):1109-1126. PubMed ID: 36571300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vortioxetine for depression in adults.
    Koesters M; Ostuzzi G; Guaiana G; Breilmann J; Barbui C
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD011520. PubMed ID: 28677828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vortioxetine: A new alternative for the treatment of major depressive disorder.
    Salagre E; Grande I; Solé B; Sanchez-Moreno J; Vieta E
    Rev Psiquiatr Salud Ment (Engl Ed); 2018; 11(1):48-59. PubMed ID: 28800937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vortioxetine in management of major depressive disorder - a favorable alternative for elderly patients?
    Danielak D
    Expert Opin Pharmacother; 2021 Jun; 22(9):1167-1177. PubMed ID: 33650935
    [No Abstract]   [Full Text] [Related]  

  • 5. Vortioxetine: a New Treatment for Major Depressive Disorder.
    Connolly KR; Thase ME
    Expert Opin Pharmacother; 2016; 17(3):421-31. PubMed ID: 26679430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vortioxetine in the Treatment of Mood Disorders Associated with Burning Mouth Syndrome: Results of an Open-Label, Flexible-Dose Pilot Study.
    Adamo D; Pecoraro G; Aria M; Favia G; Mignogna MD
    Pain Med; 2020 Jan; 21(1):185-194. PubMed ID: 31343684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vortioxetine reduces BOLD signal during performance of the N-back working memory task: a randomised neuroimaging trial in remitted depressed patients and healthy controls.
    Smith J; Browning M; Conen S; Smallman R; Buchbjerg J; Larsen KG; Olsen CK; Christensen SR; Dawson GR; Deakin JF; Hawkins P; Morris R; Goodwin G; Harmer CJ
    Mol Psychiatry; 2018 May; 23(5):1127-1133. PubMed ID: 28533517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: a 2-week, randomized, double-blind, placebo-controlled study.
    Vieta E; Florea I; Schmidt SN; Areberg J; Ettrup A
    Int Clin Psychopharmacol; 2019 Jul; 34(4):153-160. PubMed ID: 31094901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative short-term efficacy and acceptability of agomelatine versus vortioxetine in adult patients suffering from major depressive disorder.
    Kennedy SH; Grouin JM; Cadour S; Robert V; Picarel-Blanchot F
    Hum Psychopharmacol; 2018 Jan; 33(1):. PubMed ID: 29327372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double-blind, placebo-controlled study of vortioxetine in the treatment of binge-eating disorder.
    Grant JE; Valle S; Cavic E; Redden SA; Chamberlain SR
    Int J Eat Disord; 2019 Jul; 52(7):786-794. PubMed ID: 30938842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of vortioxetine on the physical symptoms of major depressive disorder.
    Christensen MC; Florea I; Lindsten A; Baldwin DS
    J Psychopharmacol; 2018 Oct; 32(10):1086-1097. PubMed ID: 30047820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-inflammatory treatment of depression: study protocol for a randomised controlled trial of vortioxetine augmented with celecoxib or placebo.
    Fourrier C; Sampson E; Mills NT; Baune BT
    Trials; 2018 Aug; 19(1):447. PubMed ID: 30126458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vortioxetine Versus Placebo for Major Depressive Disorder: A Comprehensive Analysis of the Clinical Trial Dataset.
    Iovieno N; Papakostas GI; Feeney A; Fava M; Mathew SJ; Iosifescu DI; Murrough JW; Macaluso M; Hock RS; Jha MK
    J Clin Psychiatry; 2021 Jun; 82(4):. PubMed ID: 34133089
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment Effects of Vortioxetine on Cognitive Functions in Mild Alzheimer's Disease Patients with Depressive Symptoms: A 12 Month, Open-Label, Observational Study.
    Cumbo E; Cumbo S; Torregrossa S; Migliore D
    J Prev Alzheimers Dis; 2019; 6(3):192-197. PubMed ID: 31062834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy, safety, and tolerability of vortioxetine for the treatment of major depressive disorder in patients aged 55 years or older.
    Nomikos GG; Tomori D; Zhong W; Affinito J; Palo W
    CNS Spectr; 2017 Aug; 22(4):348-362. PubMed ID: 27869048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New generation antidepressants for depression in children and adolescents: a network meta-analysis.
    Hetrick SE; McKenzie JE; Bailey AP; Sharma V; Moller CI; Badcock PB; Cox GR; Merry SN; Meader N
    Cochrane Database Syst Rev; 2021 May; 5(5):CD013674. PubMed ID: 34029378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Vortioxetine in the treatment of major depression].
    de Bartolomeis A; Fagiolini A; Maina G
    Riv Psichiatr; 2016; 51(6):215-230. PubMed ID: 27996982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy and safety of 10 mg/day vortioxetine compared to placebo for adult major depressive disorder: a meta-analysis.
    Zheng J; Wang Z; Li E
    Afr Health Sci; 2019 Mar; 19(1):1716-1726. PubMed ID: 31149002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vortioxetine improves physical and cognitive symptoms in patients with post-COVID-19 major depressive episodes.
    Di Nicola M; Pepe M; Montanari S; Spera MC; Panaccione I; Simonetti A; Sani G
    Eur Neuropsychopharmacol; 2023 May; 70():21-28. PubMed ID: 36808043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of vortioxetine in subjects with major depressive and alcohol use disorders: a 6-month retrospective analysis.
    Di Nicola M; Pepe M; Panaccione I; Moccia L; Dattoli L; Molinaro M; Sani G; Janiri L; McIntyre RS
    CNS Spectr; 2022 Feb; 27(1):73-81. PubMed ID: 32772956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.